We are a group of motivated immunologists committed to delivering the power of cytokines to patients.
Founded in 2017 by leading experts in the field of immunotherapy, Anaveon is a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction.
Our goal is to harness the power of engineered cytokines and develop novel treatments for diseases with high unmet need.
We are exploiting the power of cytokines to orchestrate immune responses by using protein engineering to create safe and effective cytokine treatments for a variety of serious diseases.
OUR APPROACH
Our first program going into clinical trials is ANV419, a selective interleukin-2 (IL-2) receptor agonist – a type of protein that can enhance a patient’s immune system in order to target and defeat tumors.
IL-2 Cancer Immunotherapy
Our pipeline includes additional programs that leverage targeted cytokines for a range of immune-mediated diseases.
Our Immunotherapy Pipeline
Years of Experience
Million CHF Funding
Days to regulatory submission
LATEST NEWS
26
May
2020
Anaveon Unveils Refreshed Brand Identity and Website
Anaveon, a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction, reveals a refreshed brand and website.
4 
10
April
2019
Anaveon Announces Appointment of Dr Allison Jeynes-Ellis to its Board of Directors
Anaveon, an immuno-oncology company, today announced that it has appointed Dr Allison Jeynes-Ellis to its Board of Directors.
3 
26
February
2019
Anaveon, a New Immuno-Oncology Company, Announces CHF 35 million Series A Financing
Anaveon, an immuno-oncology company, today announced completion of a CHF 35 million Series A financing led by Syncona Ltd and joined by the Novartis Venture Fund.
3 
Our dedicated team of experts has decades of experience in immunology, oncology and drug design. We use our deep knowledge to deliver novel drugs that address unmet medical needs.
About us
We are committed to developing treatments that benefit patients.
Science
We are developing an IL-2 immunotherapy for cancer.
Team
We are driven by the urgency of patients.
Investors
&
Partners
We are backed by more than 36 million CHF (€34 million) of funding.